Histopathologist Features Predictive of Diagnostic Concordance at Expert Level Amongst a Large International Sample of Pathologists Diagnosing Barrett’s Dysplasia Using Digital Pathology

Myrtle J. van der Wel; Helen G. Coleman; Jacques JGHM Bergman; Marnix Jansen; Sybren L. Meijer; on behalf of the BOLERO working group

doi:10.1101/19000174

ABSTRACT

Objective Guidelines recommend expert pathology review of Barrett’s oesophagus (BO) biopsies that reveal dysplasia, but there are no evidence-based standards to corroborate expert reviewer status. We investigated BO concordance rates and pathologist features predictive of diagnostic discordance amongst a large international cohort of gastrointestinal pathologists to develop a quantitative model of BO expert review.

Design Pathologists (n=55) from over 20 countries assessed 55 digitised BO biopsies from across the diagnostic spectrum, before and after viewing matched p53 immunohistochemistry. Extensive demographic and clinical experience data were obtained via online questionnaire. We calculated discordance rates and applied multivariate regression analyses to identify predictors of concordance.

Results We recorded over 6,000 individual case diagnoses. Of 2,805 H&E diagnoses, we found excellent concordance (>70%) for non-dysplastic Barrett’s oesophagus (NDBO) and high-grade dysplasia (HGD), and intermediate concordance for low-grade dysplasia (LGD, 42%) and indefinite for dysplasia (IND, 23%). Major diagnostic errors (i.e. NDBO overinterpreted as LGD/HGD or vice versa) were found in 248 diagnoses (8.8%), which reduced to 8.3% after viewing p53 labelled slides. At least 5 years of professional experience was protective against major diagnostic error for H&E slide review (OR 0.48, 95%CI 0.31-0.74). Working in a district general hospital was associated with increased odds of major diagnostic error (OR 1.76, 95%CI 1.15-2.69), however this was neutralised when pathologists viewed p53 labelled slides, suggesting a beneficial impact of p53 immunohistochemistry for this group.

Conclusion We have developed an evidence-based quantitative model of BO histopathology diagnosis at expert consensus level that will inform guideline development.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

HJC and MJ are funded by Cancer Research UK

Author Declarations

All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.

I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.

Yes